CEPHEUS - Assessment of lipid-lowering treatment in France

Head :Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Last update : 09/05/2017 | Version : 3 | ID : 6396

General

Identification

Detailed name	Assessment of lipid-lowering treatment in France
Sign or acronym	CEPHEUS
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL méthodologie de référence MR-001; Avis favorable n° 2-06-14/Avis n°2 du CCPPRB Toulouse II du 5 mai 2006; Avis favorable AFSSAPS n°060544 du 25 août 2006

General Aspects

Medical area	Cardiology Hematology
Keywords	Guidelines, LDL cholesterol, Lipid-lowering drugs, Statins, France

Scientific investigator(s) (Contact)

Name of the director	Ferrières
Surname	Jean
Address	Faculté de médecine 37 allée Jules Guesde 31073 Toulouse Cedex
Phone	+33 (0)5 61 14 59 49
Email	jean.ferrieres@univ-toulouse.fr
Unit	Département d'épidémiologie INSERM UMR1027
Organization	CHU de

Collaborations

Funding

Funding status	Private

Details	Astra Zeneca (laboratoire pharmaceutique)

Governance of the database

Sponsor(s) or organisation(s) responsible	CHU de toulouse
Organisation status	Public
Sponsor(s) or organisation(s) responsible	Promoteur : Astra Zeneca SAS 92844 Rueil Malmaison
Organisation status	Private

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	All included patients visiting a general practitioner for any reason and corresponding to the criteria are invited to participate.

Database objective

Main objective	Determine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended in guidelines.
Inclusion criteria	man or woman - adult - treated with lipid-lowering drugs for at least three months, with no dose adjustment for a minimum of six weeks

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years)

Population covered	Sick population
Gender	Male Woman
Geography area	International
Detail of the geography area	8 european countries: Belgium, France, Greece, Ireland, Netherlands, Finland, Turkey and Luxembourg

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	05/2006
Date of last collection (YYYY or MM/YYYY)	12/2006

Size of the database

Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1966 french subjects

Data

Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Biological data
Clinical data (detail)	Medical registration
Declarative data (detail)	Paper self-questionnaire
Biological data (detail)	fasting blood sample
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health care consumption and services
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption

Procedures	
Participant monitoring	No
Links to administrative sources	No

Promotion and access

Promotion	
Link to the document	http://www.sciencedirect.com/science/article/pii/S1875213608001150

Access	
Terms of data access (charter for data provision, format of data, availability delay)	Contact scientific investigator.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only